"Shares of this development-stage biotechnology company focused on the research, development and licensing of an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing have been rising steadily the last two sessions on rumors that the U.S. Government has taken a great interest in it's Homspera product and may be awarding some research grants said to be in the tens of millions of dollars."